This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Myriad Genetics To Present Five Clinical Studies At 2014 ASCO GU Cancer Symposium

SALT LAKE CITY, Jan. 23, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that results from four studies in prostate cancer with Prolaris ® and one study in renal cancer will be presented at the 2014 ASCO Genitourinary Cancers Symposium, which will be held Jan. 30-Feb. 1, 2014 in San Francisco, Calif. Prolaris is a prognostic test that accurately predicts cancer-specific death and metastases based on an analysis of 46 cell cycle progression genes. The Prolaris score is a stronger predictor of prostate cancer death and recurrence than clinical parameters such as Gleason score and PSA and has been validated in 11 clinical studies with more than 5,000 patients. The Company also will present data from a study with an investigational prognostic test in development for renal cell carcinoma. 

2014 ASCO GU – POSTER PRESENTATIONS
   
Title:  Prolaris CCP score stratifies risk for prostate cancer patients at biopsy: initial commercial results.
Presenter:  David Crawford
Date:  Thursday, Jan. 30, 11:30 a.m. to 1:00 p.m. and 5:15 to 6:45 p.m. PST (Poster Session A)
   
Title:  Cell cycle progression score significantly modifies treatment decisions in prostate cancer: Results of an ongoing registry trial.
Presenter:  Ashok Kar
Date:  Friday, Jan. 31, 12:00 to 1:30 p.m. and 5:45 to 7:15 p.m. PST ( Poster Session B)
   
Title:  Prognostic utility of the cell cycle progression score generated from needle biopsy in men treated with prostatectomy.
Presenter:  Jay Bishoff
Date:  Thursday, Jan. 30, 11:30 a.m. to 1:00 p.m. and 5:15 to 6:45 p.m. PST (Poster Session A)
   
Title:  Cell cycle progression score to predict metastatic progression of clear cell renal carcinoma after resection.
Presenter:  Erik Askeland
Date:  Saturday, Feb. 1, 6:45 to 7:55 a.m. and 11:30 a.m. to 12:30 p.m. PST ( Poster Session C)

About Prolaris ®

Prolaris is a novel prognostic test developed by Myriad Genetics that directly measures tumor cell growth characteristics for stratifying the risk of disease progression in prostate cancer patients. Prolaris provides a quantitative measure of the RNA expression levels of multiple genes related to the progression of tumor cell division. Prolaris can identify low-risk patients who may be candidates for surveillance as well as patients who may be potentially at higher risk and would benefit from closer monitoring or additional therapy. Prolaris has been proven to predict prostate cancer-specific disease progression in five published clinical trials. For more information visit: www.prolaris.com and www.myriad.com/understanding-prostate-cancer/ .

About Myriad Genetics

Myriad Genetics is a leading molecular diagnostic company dedicated to making a difference in patients' lives through the discovery and commercialization of transformative tests to assess a person's risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence. Myriad's molecular diagnostic tests are based on an understanding of the role genes play in human disease and were developed with a commitment to improving an individual's decision making process for monitoring and treating disease. Myriad is focused on strategic directives to introduce new products, including companion diagnostics, as well as expanding internationally. For more information on how Myriad is making a difference, please visit the Company's website: www.myriad.com .

Myriad, the Myriad logo and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and foreign countries. MYGN-F, MYGN-G.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,915.07 -70.54 -0.42%
S&P 500 1,964.68 -8.15 -0.41%
NASDAQ 4,396.2040 -22.83 -0.52%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs